| 'Sisterhood' celebrates triumph, struggles with breast cancer
In a massive ballroom with chandeliers and gold-lined ceilings, she dined on herb-roasted chicken, sauteed vegetables and mashed new potatoes. She took home a gift bag stuffed with Estee Lauder perfume, a Rachael Ray cookbook, Chapstick and a box of granola bars. .
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast ...
REDWOOD CITY, Calif., July 2 /PRNewswire-FirstCall/ -- Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia. MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy. "Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market." The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients.
Cancer on my mind
As an oncologist, I am interested in the lure of alternative medicine. And so I have tried to understand why, in spite of all the scientific evidence at hand, there are many amongst us who do not want to undergo conventional cancer treatment surgery, radiotherapy, chemotherapy and targeted therapy but instead risk being treated by unproven and potentially dangerous alternative therapies. I am sure the lack of science education plays a role. Science is more than the description of plants and animals. It is more than technology and engineering. To understand science is to understand the principles, methodologies and philosophy of science. .
|
